companies with glp 1 drugs Market Overview: GLP-1 Agonists and the Obesity Market | Blog companies working on glp-1 drugs

In urothelial carcinoma of the bladder (UCB), a widespread increase in mRNA m5C methylation was observed, with 4,126 hypermethylated m5C sites across 2,041 mRNAs in tumor tissues compared to normal controls

10.1007/s13311-019-00766-9 108 RzepeckiA

Glossary Agrp Agouti-related protein AKT Protein kinase B (AKT) AMPK AMP-activated protein kinase ARC Arcuate nucleus BAT Brown adipose tissue BMI Body mass index cAMP Cyclic adenosine monophosphate C/EBP CCAAT/enhancer-binding protein beta DA Dopamine DLN Dorsolateral nucleus DMN Dorsomedial nucleus D2R Dopamine D2 receptor E2 17-estradiol EGF Epidermal growth factor FSH Follicle-stimulating hormone GAS -Interferon activation sequence GLP-1 Glucagon-like peptide-1 GLP-1 RAs Glucagon-like peptide-1 receptor agonists GnRH Gonadotropin-releasing hormone HDL-C High-density lipoprotein cholesterol HPG Hypothalamicpituitarygonadal (axis) HPRL Hyperprolactinemia ICV Intraventricular (intracerebroventricular) IL-1 Interleukin-1 beta IL-6 Interleukin-6 JAK2 Janus kinase 2 kDa Kilodalton LDL-C Low-density lipoprotein cholesterol LH Luteinizing hormone MAPK Mitogen-activated protein kinase MASLD Metabolic dysfunctionassociated fatty liver disease PY Neuropeptide Y PI3K Phosphoinositide 3-kinase PPAR Peroxisome proliferator-activated receptor gamma PRL Prolactin PRLR Prolactin receptor Ras Rat sarcoma (Ras) signaling family SCN Suprachiasmatic nucleus STAT Signal transducer and activator of transcription TIDA Tuberoinfundibular dopaminergic TNF- Tumor necrosis factor alpha TRH Thyrotropin-releasing hormone

Singh et al., 2007)